PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes

Informations projet

PanINSULA

N° de convention de subvention: 828384

DOI

10.3030/828384

Projet clôturé

Date de signature de la CE 19 Juillet 2018

Date de début 1 Août 2018

Date de fin 30 Novembre 2018

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

PANCRYOS APS
Denmark

Periodic Reporting for period 1 - PanINSULA (PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes)

Période du rapport: 2018-08-01 au 2018-11-30

Résumé du contexte et des objectifs généraux du projet

Type 1 Diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stop producing insulin - the hormone that controls blood-sugar levels. Insulin therapy, CGMs and insulin pumps try to mimic the function of the beta cell and require the patient or a computer to perform many of the steps such as testing blood, evaluating the results and administering insulin. PanCryos is developing a next generation stem cell derived therapy, PanINSULA, to treat T1D naturally without the need for outside intervention. The overall objectives of the project are implementing a GMP-compliant production protocol and clinically validating PanINSULA.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During Phase 1 PanCryos assessed both the technical and business feasibility of PanINSULA. A product development plan addressing production setup and clinical validation requirements to ensure PanINSULA market readiness was drafted. Third parties to participate in the product development were contacted. A market assessment (including assessment of market size, customers and competitors) was carried out, the business model was refined and financial projections were prepared.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Pancryos patented technology, in contrast to other available competing technologies, enables both purification and automation ensuring unparalleled safety and cost-efficient scalability and manufacturability of the final cell product PanINSULA which can then be delivered to T1D patients as a naturally-acting alternative to existing solutions such as insulin therapy, CGMs and insulin pumps which requires careful and constant management. PanINSULA commercialisation will improve the quality of life of millions of patients suffering from diabetes.

PanCryos